hidradenitis suppurativa

News

MSD advances on a broad front with TL1A drug tulisokibart

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake.

News

Fresh from IPO, Acelyrin's lead drug fails clinical trial

Acelyrin has been flying high in the wake of an unusually large initial public offering (IPO) in May, but came down to earth with a bump today after a failed clinical tria

News

Cosentyx nod ends 10-year drought in new biologics for HS

Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i

News

Acelyrin files IPO – is a biotech comeback on the way?

Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con

MSD advances on a broad front with TL1A drug tulisokibart

MSD rumoured to be eyeing $3bn+ MoonLake takeover

Fresh from IPO, Acelyrin's lead drug fails clinical trial

Cosentyx nod ends 10-year drought in new biologics for HS

Acelyrin files IPO – is a biotech comeback on the way?

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

hidradenitis suppurativa

Editor's Picks